Efficacy of the AS04-adjuvanted HPV-16/18 vaccine in young Chinese women with oncogenic HPV infection at baseline: post-hoc analysis of a randomized controlled trial
- PMID: 33180670
- PMCID: PMC8018349
- DOI: 10.1080/21645515.2020.1829411
Efficacy of the AS04-adjuvanted HPV-16/18 vaccine in young Chinese women with oncogenic HPV infection at baseline: post-hoc analysis of a randomized controlled trial
Abstract
Human papillomavirus (HPV) vaccines are efficacious against HPV infections and associated lesions in women HPV-naïve at vaccination. However, vaccine efficacy (VE) against oncogenic, high-risk HPV (HR-HPV) types in women infected with any other HR-HPV type at first vaccination (baseline) remains unclear. This post-hoc analysis of a phase II/III study (NCT00779766) evaluated AS04-adjuvanted HPV-16/18 (AS04-HPV-16/18) VE against HR-HPV type infection in 871 Chinese women aged 18-25 years over a 72-month follow-up period. Study participants were DNA-negative at baseline to HR-HPV type(s) considered for VE and DNA-positive to any other HR-HPV type. Initial serostatus was not considered. Baseline DNA prevalence was 14.6% for any HR-HPV type and 10.6% excluding HPV-16/18. In the total vaccinated cohort for efficacy, VE against 6-month and 12-month HPV-16/18 persistent infections (PIs) in women DNA-negative to HPV-16/18 but DNA-positive to any other HR-HPV type at baseline was 100.0% (95% Confidence Interval [CI]: 79.8-100.0) and 100.0% (95%CI: 47.2-100.0), respectively. VE against HPV-16/18 incident infections in women DNA-positive to one vaccine type but DNA-negative to the other one at baseline was 66.8% (95%CI: -18.9-92.5). VE against HPV-31/33/45 incident infections, in women DNA-positive to HPV-16/18 and DNA-negative to the considered HPV type at baseline was 71.0% (95%CI: 27.3-89.8). No HPV-16/18 PIs were observed in vaccinated women with non-vaccine HPV A7/A9 species cervical infection at baseline. These findings indicated that women with existing HR-HPV infection at vaccination might still benefit from the AS04-HPV-16/18 vaccine. However, this potential benefit needs further demonstration in the future.
Keywords: China; Human papillomavirus; cervical cancer; clinical trial; efficacy; infection; prevention; vaccines.
Conflict of interest statement
All authors have completed the Unified Competing Interest form at
Figures
Similar articles
-
Impact of HPV-16/18 AS04-adjuvanted vaccine on preventing subsequent infection and disease after excision treatment: post-hoc analysis from a randomized controlled trial.BMC Infect Dis. 2020 Nov 16;20(1):846. doi: 10.1186/s12879-020-05560-z. BMC Infect Dis. 2020. PMID: 33198657 Free PMC article. Clinical Trial.
-
Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: results from a randomized controlled trial.Int J Cancer. 2014 Dec 1;135(11):2612-22. doi: 10.1002/ijc.28897. Epub 2014 May 20. Int J Cancer. 2014. PMID: 24740596 Free PMC article. Clinical Trial.
-
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.Lancet Oncol. 2012 Jan;13(1):100-10. doi: 10.1016/S1470-2045(11)70287-X. Epub 2011 Nov 8. Lancet Oncol. 2012. PMID: 22075170 Clinical Trial.
-
AS04-adjuvanted human papillomavirus (HPV) types 16 and 18 vaccine (Cervarix®): a review of its use in the prevention of premalignant cervical lesions and cervical cancer causally related to certain oncogenic HPV types.Drugs. 2011 Mar 5;71(4):465-88. doi: 10.2165/11206820-000000000-00000. Drugs. 2011. PMID: 21395359 Review.
-
Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases.Expert Rev Vaccines. 2016;15(3):367-87. doi: 10.1586/14760584.2016.1124763. Expert Rev Vaccines. 2016. PMID: 26902666 Review.
Cited by
-
Current status and future directions for the development of human papillomavirus vaccines.Front Immunol. 2024 Jun 25;15:1362770. doi: 10.3389/fimmu.2024.1362770. eCollection 2024. Front Immunol. 2024. PMID: 38983849 Free PMC article. Review.
-
HPV Infection Prevalence, Vaccination-Related Knowledge, Attitudes, and Barriers Among Women Aged 30-64 in Shenzhen, China: A Cross-Sectional Study.Vaccines (Basel). 2025 May 25;13(6):561. doi: 10.3390/vaccines13060561. Vaccines (Basel). 2025. PMID: 40573892 Free PMC article.
-
Impact of human papillomavirus vaccines in the reduction of infection, precursor lesions, and cervical cancer: A systematic literature review.Hum Vaccin Immunother. 2025 Dec;21(1):2497608. doi: 10.1080/21645515.2025.2497608. Epub 2025 Jun 9. Hum Vaccin Immunother. 2025. PMID: 40485552 Free PMC article. Review.
-
Effectiveness of interventions to improve vaccine efficacy: a systematic review and meta-analysis.Syst Rev. 2025 May 9;14(1):105. doi: 10.1186/s13643-025-02856-6. Syst Rev. 2025. PMID: 40346627 Free PMC article.
-
Immunogenicity, efficacy, and safety of human papillomavirus vaccine: Data from China.Front Immunol. 2023 Mar 13;14:1112750. doi: 10.3389/fimmu.2023.1112750. eCollection 2023. Front Immunol. 2023. PMID: 36993948 Free PMC article. Review.
References
-
- Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374:301–14. doi:10.1016/S0140-6736(09)61248-4. - DOI - PubMed
-
- Huh WK, Joura EA, Giuliano AR, Iversen OE, de Andrade RP, Ault KA, Bartholomew D, Cestero RM, Fedrizzi EN, Hirschberg AL, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial. Lancet. 2017;390:2143–59. doi:10.1016/S0140-6736(17)31821-4. - DOI - PubMed